CMS Reviews Medicare Coverage With Evidence Development May 9
This article was originally published in The Pink Sheet Daily
Executive Summary
Open door forum will consider factors in providing Coverage with Evidence Development. Part B drugs are eligible for CED; comment deadline on CED draft guidance is June 6.
You may also be interested in...
House Appropriations Subcommittee Plans FDA Hearing July 26
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Second Quarter Earnings Season Heats Up
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
Project BioShield Is Topic Of House Hearings July 12 And 14
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.